Global Gastroesophageal Reflux Disease Therapeutics Market Size To Worth USD 5.97 Billion by 2033 | CAGR of 2.02%
Category: HealthcareGlobal Gastroesophageal Reflux Disease Therapeutics Market Size To Worth USD 5.97 Billion by 2033
According to a research report published by Spherical Insights & Consulting, the Global Gastroesophageal Reflux Disease Therapeutics Market Size is to Grow from USD 4.89 Billion in 2023 to USD 5.97 Billion by 2033, at a Compound Annual Growth Rate (CAGR) of 2.02% during the projected period.
Get more details on this report -
Browse key industry insights spread across 277 pages with 120 Market data tables and figures & charts from the report on the "Global Gastroesophageal Reflux Disease Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Route of Administration (Parental Route, Oral Route), By Drug Type (H2 Receptor Blockers, Proton Pump Inhibitors, Antacids, Pro-Kinetic Agents), By Distribution Channel (Retail, Online, Hospital), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/gastroesophageal-reflux-disease-therapeutics-market
Gastroesophageal Reflux Disease (GERD) is a chronic digestive disorder where stomach acid or bile flows back into the esophagus, causing irritation and inflammation. It is often caused by a weakened lower esophageal sphincter, which prevents stomach contents from rising into the esophagus. Factors such as obesity, certain foods, smoking, and pregnancy can exacerbate the condition. GERD therapeutics, such as proton pump inhibitors (PPIs), H2 receptor blockers, antacids, and pro-kinetic agents, help manage and alleviate symptoms of the disorder. These treatments relieve discomfort, prevent complications like esophagitis, and improve the quality of life for those affected. These factors drives the market. However, the long-term use of PPIs can lead to nutrient deficiencies, increasing the risk of bone fractures, anemia, and other health issues that may be responsible for hampering the market growth.
The oral route segment is anticipated to hold the highest share of the global gastroesophageal reflux disease therapeutics market during the projected timeframe.
Based on the route of administration, the global gastroesophageal reflux disease therapeutics market is divided into parental route and oral route. Among these, the oral route segment is anticipated to hold the highest share of the global gastroesophageal reflux disease therapeutics market during the projected timeframe. Oral medications like PPIs, H2 receptor antagonists, and antacids are commonly prescribed for GERD due to their convenience, ease of administration, and effectiveness. The growing availability of over-the-counter treatments is driving market growth.
The proton pump inhibitors segment is anticipated to grow at the fastest pace in the global gastroesophageal reflux disease therapeutics market during the projected timeframe.
Based on the drug type, the global gastroesophageal reflux disease therapeutics market is divided into H2 receptor blockers, proton pump inhibitors, antacids, and pro-kinetic agents. Among these, the proton pump inhibitors segment is anticipated to grow at the fastest pace in the global gastroesophageal reflux disease therapeutics market during the projected timeframe. PPIs effectively manage GERD by reducing stomach acid production, treating esophagitis, and preventing complications, driving demand and resulting in significant growth in the PPI segment
The online segment is anticipated to grow at the fastest pace in the global gastroesophageal reflux disease therapeutics market during the projected timeframe.
Based on the distribution channel, the global gastroesophageal reflux disease therapeutics market is divided into retail, online, and hospital. Among these, the online segment is anticipated to grow at the fastest pace in the global gastroesophageal reflux disease therapeutics market during the projected timeframe. The online GERD treatment market is expanding rapidly due to e-commerce, convenience, self-medication, and over-the-counter treatments, with the COVID-19 pandemic boosting online shopping for healthcare products.
North America is expected to hold the largest share of the global gastroesophageal reflux disease therapeutics market over the forecast period.
Get more details on this report -
North America is expected to hold the largest share of the global gastroesophageal reflux disease therapeutics market over the forecast period. The region’s GERD market is dominated by lifestyle factors, infrastructure, and healthcare spending, with leading pharmaceutical companies researching advanced treatments and a large population base. The region's large population base and growing awareness of GERD and its symptoms contribute to its leading position in the GERD therapeutics market.
Asia Pacific is predicted to grow at the fastest pace in the global gastroesophageal reflux disease therapeutics market during the projected timeframe. The GERD therapeutics market is experiencing significant growth in the region due to changing dietary habits, obesity, urbanization, a middle-class population, improved healthcare infrastructure, and increased pharmaceutical investments.
Major vendors in the Global Gastroesophageal Reflux Disease Therapeutics Market include Merck & Co., Inc., Johnson & Johnson, Sanofi, Dr. Reddy's Laboratories, Mylan N.V., Pfizer Inc., Abbott Laboratories, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Bayer AG, Eisai Co., Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., AstraZeneca, and Others.
Recent Developments
- In June 2024, Takeda Pharmaceuticals secured non-exclusive patent licensing agreements with Sun Pharma and Cipla to commercialize Vonoprazan tablets in India.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global Gastroesophageal Reflux Disease Therapeutics market based on the below-mentioned segments:
Global Gastroesophageal Reflux Disease Therapeutics Market, By Route of Administration
- Parental Route
- Oral Route
Global Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type
- H2 Receptor Blockers
- Proton Pump Inhibitors
- Antacids
- Pro-Kinetic Agents
Global Gastroesophageal Reflux Disease Therapeutics Market, By Distribution Channel
- Retail
- Online
- Hospital
Global Gastroesophageal Reflux Disease Therapeutics Market, Regional
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?